Money Matters, Simplified.
Business skillness
Potential Can't Buy Me Love
Thu, 08/06/2009 - 02:33 by Brian Orelli
 It's sad when investors can't get excited about a company doubling its earnings per share and posting 19% growth in sales of its drug, but that's exactly the spot that Onyx Pharmaceuticals (Nasdaq: ONXX) finds itself in. Shares are down some 14% at the moment. |